Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). No substantive Regulation FD disclosure in the provided excerpt.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- No substantive Regulation FD disclosure in the provided excerpt
- Excerpt contains only standard Exchange Act liability and incorporation-by-reference disclaimer language
Item 8.01 · Other Events
- FDA alignment on adaptive Phase 2 Lyme-prevention study design for TNX-4800, reducing regulatory uncertainty
- Planned randomized placebo-controlled study: 3,300 adults across two seasons
- Primary endpoint: Lyme prevention at six months; secondary endpoint: prevention at three months
- Safety assessment over 52 weeks, with most enrollment expected during 2028 season
- Investigational product manufacturing on track for study-site delivery in Q1 2027
Item EX-99.1 · Exhibit EX-99.1
- FDA alignment supports planned adaptive Phase 2 field study start in Q1 2027, pending final protocol approval
- Randomized placebo-controlled study targeting approximately 3,300 adults across two Lyme seasons
- TNX-4800 regimen: 450 mg subcutaneous injections at baseline and approximately three months later
- Primary endpoint: Lyme disease prevention through six months; safety and tolerability followed for 52 weeks
- Lower-than-expected infection rates could extend enrollment into 2029, creating timeline and execution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.